Clarivate Plc Q2 2026 Earnings Recap

CLVT Q2 2026 August 2, 2026

Get alerts when CLVT reports next quarter

Clarivate's shares plunged 16.2% following the quarter, reflecting investor disappointment mainly due to cautious outlook and ongoing deceleration in the Intellectual Property segment’s growth despite progress in AI initiatives and stable organic ACV growth in other segments.

Earnings Per Share Beat

$0.19 vs $0.18 est.

+4.6% surprise

Revenue Miss

587300000 vs 589729300 est.

-0.4% surprise

Market Reaction

1-Day -2.02%

5-Day -8.08%

See CLVT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Organic ACV growth improved modestly to 1.5% overall, driven by 2% growth in Academia & Government and Life Sciences & Healthcare segments.
Intellectual Property segment’s recurring organic revenue remained flat, with growth only expected in the second half, signaling ongoing challenges.
Profit margin expanded slightly to over 42%, aided by disciplined cost management.
Management announced the divestiture of the Life Sciences & Healthcare segment, aiming to sharpen focus on AI-driven intelligence and simplify the business model.
New AI product launches, including Nexus Connect and IP-1, indicate innovation progress but have yet to reverse investor concerns about near-term growth trajectory.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CLVT on AllInvestView.

Previous Q2 2025